ELTROMBOPAG OLAMINE

Eltrombopag Olamine is a thrombopoietin receptor agonist used to stimulate platelet production in patients with thrombocytopenia. It is commonly prescribed for chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with hepatitis.

Indications

-Chronic immune thrombocytopenia (ITP) in adults and children who have had an insufficient response to other treatments -Severe aplastic anemia -Thrombocytopenia in patients with chronic hepatitis C to allow for interferon-based therapy

Dosage

-Adult Dose: Typically, 50 mg once daily. However, patients of East Asian descent or those with hepatic impairment may start at 25 mg. -Pediatric Dose: Varies based on body weight and indication. -The dose may be adjusted based on platelet response and liver function.

Contra-Indications

-Hypersensitivity to Eltrombopag or any of its components -Severe hepatic impairment -Patients with a history of thromboembolic events

Special Precautions

-Regular monitoring of liver function tests -Increased risk of thrombotic events at higher platelet counts -Should not be used as an emergency treatment for bleeding -Avoid taking with dairy products, calcium-rich foods, or antacids, as they reduce drug absorption

Side Effects

-Nausea, vomiting -Headache -Liver enzyme elevation -Fatigue -Thromboembolic events in rare cases

Drug Interactions

-Antacids and calcium-containing foods reduce absorption -Strong CYP1A2 inhibitors/inducers may alter drug metabolism -Increased risk of hepatotoxicity with other hepatotoxic drugs